Pfizer 2006 Annual Report Download - page 77

Download and view the complete annual report

Please find page 77 of the 2006 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

76 2006 Financial Report
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2006
Revenues $11,747 $11,741 $12,280 $12,603
Costs and expenses 7,178 7,877 8,070 10,060
Acquisition-related in-process research and development charges — 513 — 322
Restructuring charges and acquisition-related costs 299 268 249 507
Income from continuing operations before provision for taxes
on income, and minority interests 4,270 3,083 3,961 1,714
Provision/(benefit) for taxes on income 262 790 717 223
Minority interests 2352
Income from continuing operations 4,006 2,290 3,239 1,489
Discontinued operations:
Income from discontinued operations—net of tax 102 108 120 103
Gains on sales of discontinued operations—net of tax 3 17 3 7,857
Discontinued operations—net of tax 105 125 123 7,960
Cumulative effect of a change in accounting principles ————
Net income $ 4,111 $ 2,415 $ 3,362 $ 9,449
Earnings per common share—basic:
Income from continuing operations $ 0.55 $ 0.31 $ 0.45 $ 0.21
Discontinued operations—net of tax 0.01 0.02 0.02 1.11
Cumulative effect of a change in accounting principles ————
Net income $ 0.56 $ 0.33 $ 0.47 $ 1.32
Earnings per common share—diluted:
Income from continuing operations $ 0.55 $ 0.31 $ 0.44 $ 0.21
Discontinued operations—net of tax 0.01 0.02 0.02 1.11
Cumulative effect of a change in accounting principles ————
Net income $ 0.56 $ 0.33 $ 0.46 $ 1.32
Cash dividends paid per common share $ 0.24 $ 0.24 $ 0.24 $ 0.24
Stock prices
High $ 26.84 $ 25.72 $ 28.58 $ 28.60
Low $ 23.60 $ 22.51 $ 22.16 $ 23.75
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies
Basic and diluted EPS are computed independently for each of the
periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
All financial information reflects our Consumer Healthcare
business as discontinued operations (see Note 3. Discontinued
Operations).
Acquisition-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisitions of PowderMed and Rinat (see Note 2. Acquisitions).
Restructuring charges and acquisition-related costs includes
restructuring charges primarily related to our AtS productivity
initiative (see Note 4. Adapting to Scale Productivity Initiative).
As of January 31, 2007, there were 242,836 holders of record of
our common stock (symbol PFE).